CSIMarket
 


Navidea Biopharmaceuticals Inc   (NAVB)
Other Ticker:  
 

Cumulative Navidea Biopharmaceuticals Inc 's Quick Ratio for Trailing Twelve Months Period

NAVB's Quick Ratio for Trailing Twelve Months Period and Cash & cash equivalent, Current Liabilities growth


Select the Comparisons : Select the Ratio:

NAVB Quick Ratio for Trailing Twelve Months Period

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Growth -5.39 % 56.07 % 88.77 % 87.23 % 105.86 %
Y / Y Cash & cash equivalent Growth -16 % 1773.06 % -97.22 % -52.83 % -35.89 %
Quick Ratio for Trailing Twelve Months Period 0.34 0.36 0.21 0.28 0.43
Total Ranking # 2307 # 2416 # 3047 # 3356 # 2837
Seq. Current Liabilities Growth -3.94 % -10.21 % -6.78 % 17.67 % 58.45 %
Seq. Cash & cash equivalent Growth -37.09 % 18079.82 % -98.31 % -56.62 % 1302.63 %


Quick Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Sep 30 2023
On the trailing twelve months basis Despite year on year decrease in Navidea Biopharmaceuticals Inc 's average Current Liabilities to $8 millions, Quick Ratio for Trailing Twelve Months Period to 0.34 below company average Quick Ratio for Trailing Twelve Months Period.
Quick Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within In Vitro & In Vivo Diagnostic Substances industry 13 other companies have achieved higher Quick Ratio for Trailing Twelve Months Period than Navidea Biopharmaceuticals Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Quick Ratio?
Learn more about NAVB
Quick Ratio NAVB in the most recent quarter
Quick Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 14
Sector # 811
S&P 500 # 2007


Quick Ratio for Trailing Twelve Months Period Statistics
High Average Low
1.48 0.67 0.05
(Dec 31 2021)   (Dec 31 2016)




Companies with similar average Quick Ratio for Trailing Twelve Months Period for 12 months ending Sep 30 2023, within In Vitro & In Vivo Diagnostic Substances Industry Quick Ratio for Trailing Twelve Months Period
Alpha Teknova Inc   0.93 
Volitionrx Limited  0.82 
Myriad Genetics Inc   0.73 
Nymox Pharmaceutical Corporation  0.68 
Quotient Limited  0.66 
Lucira Health Inc   0.50 
Trinity Biotech Plc  0.49 
Navidea Biopharmaceuticals Inc   0.48 
Quidelortho Corp  0.29 
Idexx Laboratories Inc  0.16 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com